MX337862B - Composiciones y métodos para el tratamiento de la esclerosis multiple. - Google Patents
Composiciones y métodos para el tratamiento de la esclerosis multiple.Info
- Publication number
- MX337862B MX337862B MX2010011846A MX2010011846A MX337862B MX 337862 B MX337862 B MX 337862B MX 2010011846 A MX2010011846 A MX 2010011846A MX 2010011846 A MX2010011846 A MX 2010011846A MX 337862 B MX337862 B MX 337862B
- Authority
- MX
- Mexico
- Prior art keywords
- fluids
- electrokinetically
- altered
- membrane
- therapeutic compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
La presente invención se refiere a fluidos alterados por electrocinética (fluidos electrocinéticos enriquecidos con gas) que comprenden una solución acuosa iónica de nanoestructuras que contienen oxígeno estabilizadas por carga en una cantidad suficiente para proporcionar la modulación de al menos un potencial de membrana celular y conductividad de la membrana celular, y las composiciones terapéuticas y los métodos para su uso en el tratamiento de afecciones o enfermedades inflamatorias neurodegenerativas o al menos un síntoma de éstas. Las composiciones terapéuticas y los fluidos alterados por electrocinética y los métodos incluyen los fluidos acuosos iónicos alterados por electrocinética opcionalmente en combinación con otros agentes terapéuticos. Aspectos particulares proporcionan la regulación o la modulación de la transducción de la señal intracelular asociada con dicha respuesta inflamatoria por la modulación de al menos una de las membranas celulares, potencial de membrana, proteínas de la membrana tales como los receptores de membrana, que incluyen pero no se limitan a los receptores acoplados a las proteínas G (GPCR), y uniones intercelulares (por ejemplo, uniones herméticas, uniones comunicantes, unión adherente y desmosomas). Otras modalidades incluyen las rutas particulares de administración o las formulaciones de los fluidos alterados por electrocinética (por ejemplo, los fluidos y soluciones enriquecidos con gas alterados por electrocinética) y las composiciones terapeúticas. Una composición para usarse en el tratamiento de en enfermedad ó condición neurodegenerativa inflamatoria, que comprende un fluido acuoso alterado electrocinéticamente que comprende una solución acuosa iónica de nanoburbujas estabilizadas por carga que contienen oxígeno con un diámetro promedio de menos de 100 nanómetros, en donde dicha composición está adaptada para ser administrable un sujeto en necesidad del mismo en una cantidad terapéuticamente eficaz adecuada para proporcionar, tras el contacto de una célula viva por el fluido acuoso alterado electrocinéticamente, la modulación de al menos una de potencial de membrana celular, y conductividad de la membrana celular, en donde una enfermedad neurodegenerativa inflamatoria o al menos un síntoma de la misma es tratada.
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4833208P | 2008-04-28 | 2008-04-28 | |
| US4834708P | 2008-04-28 | 2008-04-28 | |
| PCT/US2008/081021 WO2009055614A1 (en) | 2007-10-25 | 2008-10-23 | Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction |
| US12/256,774 US20090227018A1 (en) | 2007-10-25 | 2008-10-23 | Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction |
| PCT/US2008/081202 WO2009055729A1 (en) | 2007-10-25 | 2008-10-24 | Compositions and methods for treating inflammation |
| US12/258,210 US20090274730A1 (en) | 2007-10-25 | 2008-10-24 | Compositions and methods for treating inflammation |
| PCT/US2009/041852 WO2009134728A2 (en) | 2008-04-28 | 2009-04-27 | Compositions and methods for treating multiple sclerosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2010011846A MX2010011846A (es) | 2011-04-11 |
| MX337862B true MX337862B (es) | 2016-03-16 |
Family
ID=43352974
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2010011846A MX337862B (es) | 2008-04-28 | 2009-04-27 | Composiciones y métodos para el tratamiento de la esclerosis multiple. |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP2282719B1 (es) |
| JP (2) | JP5539965B2 (es) |
| CN (1) | CN102076326B (es) |
| AU (1) | AU2009241365B2 (es) |
| BR (1) | BRPI0911612A2 (es) |
| CA (1) | CA2722658C (es) |
| MX (1) | MX337862B (es) |
| WO (1) | WO2009134728A2 (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007308840C1 (en) | 2006-10-25 | 2014-09-25 | Revalesio Corporation | Methods of therapeutic treatment of eyes and other human tissues using an oxygen-enriched solution |
| US9523090B2 (en) | 2007-10-25 | 2016-12-20 | Revalesio Corporation | Compositions and methods for treating inflammation |
| US9745567B2 (en) | 2008-04-28 | 2017-08-29 | Revalesio Corporation | Compositions and methods for treating multiple sclerosis |
| US10125359B2 (en) | 2007-10-25 | 2018-11-13 | Revalesio Corporation | Compositions and methods for treating inflammation |
| EP2285347A4 (en) | 2008-05-01 | 2011-09-21 | Revalesio Corp | COMPOSITIONS AND METHODS OF TREATING DISORDERS OF THE DIGESTION SYSTEM |
| AU2009308362B2 (en) * | 2008-10-22 | 2016-02-04 | Revalesio Corporation | Compositions and methods for treating thymic stromal lymphopoietin (TSLP)-mediated conditions |
| US8815292B2 (en) | 2009-04-27 | 2014-08-26 | Revalesio Corporation | Compositions and methods for treating insulin resistance and diabetes mellitus |
| BR112012027905A2 (pt) * | 2010-04-30 | 2015-09-08 | Revalesio Corp | métodos e composições para proteger contra agentes neurotóxicos |
| BR112012028540A2 (pt) * | 2010-05-07 | 2016-07-26 | Revalesio Corp | composições e métodos para melhorar desempenho fisiológico e tempo de recuperação |
| AU2011289172B2 (en) | 2010-08-12 | 2015-09-24 | Revalesio Corporation | Compositions and methods for treatment of taupathy |
| US20120263764A1 (en) * | 2011-04-13 | 2012-10-18 | Revalesio Corporation | Compositions and methods for inhibiting and/or modulating effector t-cells involved in inflammatory neurodegenerative disease |
| CN103505731A (zh) * | 2012-06-15 | 2014-01-15 | 中国药科大学 | 1型半胱氨酰白三烯受体拮抗剂在制备用于治疗阿尔茨海默病的药物中的用途 |
| US9763992B2 (en) | 2014-02-13 | 2017-09-19 | Father Flanagan's Boys' Home | Treatment of noise induced hearing loss |
| JP6921006B2 (ja) * | 2015-06-15 | 2021-08-18 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 老化関連症状を治療するための方法および組成物 |
| KR102162400B1 (ko) * | 2016-05-13 | 2020-10-06 | 시그마 테크놀로지 유겐가이샤 | 생체 투여 가능한 수용액 및 그 제조 방법 |
| WO2020262540A1 (ja) * | 2019-06-26 | 2020-12-30 | 武田薬品工業株式会社 | トランスフェクション方法 |
| US11686208B2 (en) | 2020-02-06 | 2023-06-27 | Rolls-Royce Corporation | Abrasive coating for high-temperature mechanical systems |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH1157720A (ja) * | 1996-11-07 | 1999-03-02 | Honda Motor Co Ltd | 電解機能水、その製造方法及び製造装置 |
| US7654728B2 (en) * | 1997-10-24 | 2010-02-02 | Revalesio Corporation | System and method for therapeutic application of dissolved oxygen |
| US6386751B1 (en) | 1997-10-24 | 2002-05-14 | Diffusion Dynamics, Inc. | Diffuser/emulsifier |
| US6426066B1 (en) * | 2000-01-12 | 2002-07-30 | California Pacific Labs, Inc. | Use of physiologically balanced, ionized, acidic solution in wound healing |
| WO2001062742A1 (en) | 2000-02-21 | 2001-08-30 | Astrazeneca Ab | Piperidine- and piperazine substituted n-hydroxyformamides as inhibitors of metalloproteinases |
| US6649145B2 (en) * | 2001-02-01 | 2003-11-18 | Hydron Technologies, Inc. | Compositions and method of tissue superoxygenation |
| SE0100902D0 (sv) | 2001-03-15 | 2001-03-15 | Astrazeneca Ab | Compounds |
| US7396441B2 (en) * | 2002-02-22 | 2008-07-08 | Aqua Innovations, Inc. | Flow-through oxygenator |
| US20030232114A1 (en) * | 2002-06-13 | 2003-12-18 | Nikola Dekleva | Method for liquid enrichment with oxygen and applications of enriched liquids |
| AU2002321678A1 (en) * | 2002-09-09 | 2004-03-29 | Boros Béla | Oxygen-enriched water, treated within a magnetic field and heavy water |
| US7723349B2 (en) | 2003-04-24 | 2010-05-25 | Incyte Corporation | Aza spiro alkane derivatives as inhibitors of metalloproteases |
| JP4144669B2 (ja) * | 2004-03-05 | 2008-09-03 | 独立行政法人産業技術総合研究所 | ナノバブルの製造方法 |
| SE0400850D0 (sv) | 2004-03-30 | 2004-03-31 | Astrazeneca Ab | Novel Compounds |
| SE0403086D0 (sv) | 2004-12-17 | 2004-12-17 | Astrazeneca Ab | Compounds |
| CA2513350A1 (en) * | 2005-03-02 | 2006-09-02 | Sydney West Area Health Service | Treatment for multiple sclerosis |
| WO2007087637A2 (en) | 2006-01-26 | 2007-08-02 | Washington State University Research Foundation | Compositions and methods using matrix metalloproteinase (mmp) inhibitors for treating cognitive impairment characterized by persistent or sustained mmp expression and/or activity |
| US8697120B2 (en) * | 2006-05-01 | 2014-04-15 | Johns Hopkins University | Method and use of nano-scale devices for reduction of tissue injury in ischemic and reperfusion injury |
| CA2667614A1 (en) * | 2006-10-25 | 2008-09-25 | Revalesio Corporation | Method of wound care and treatment |
| AU2007308840C1 (en) | 2006-10-25 | 2014-09-25 | Revalesio Corporation | Methods of therapeutic treatment of eyes and other human tissues using an oxygen-enriched solution |
| AU2007308838B2 (en) | 2006-10-25 | 2014-03-13 | Revalesio Corporation | Mixing device and output fluids of same |
| EP2215260A4 (en) * | 2007-10-25 | 2011-04-20 | Revalesio Corp | COMPOSITIONS AND METHOD FOR MODULATING CELL MEMBRANE-IMPROVED INTRA-CELLULAR SIGNAL TRANSMISSION |
| AU2009308362B2 (en) * | 2008-10-22 | 2016-02-04 | Revalesio Corporation | Compositions and methods for treating thymic stromal lymphopoietin (TSLP)-mediated conditions |
-
2009
- 2009-04-27 JP JP2011507562A patent/JP5539965B2/ja active Active
- 2009-04-27 MX MX2010011846A patent/MX337862B/es active IP Right Grant
- 2009-04-27 AU AU2009241365A patent/AU2009241365B2/en active Active
- 2009-04-27 BR BRPI0911612A patent/BRPI0911612A2/pt not_active IP Right Cessation
- 2009-04-27 CA CA2722658A patent/CA2722658C/en active Active
- 2009-04-27 EP EP09739530.5A patent/EP2282719B1/en active Active
- 2009-04-27 CN CN200980124930.5A patent/CN102076326B/zh active Active
- 2009-04-27 WO PCT/US2009/041852 patent/WO2009134728A2/en active Application Filing
-
2014
- 2014-05-01 JP JP2014094570A patent/JP5869612B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2014169307A (ja) | 2014-09-18 |
| WO2009134728A3 (en) | 2010-01-21 |
| AU2009241365A1 (en) | 2009-11-05 |
| EP2282719A2 (en) | 2011-02-16 |
| JP2011523627A (ja) | 2011-08-18 |
| JP5869612B2 (ja) | 2016-02-24 |
| CN102076326A (zh) | 2011-05-25 |
| AU2009241365B2 (en) | 2015-01-22 |
| WO2009134728A2 (en) | 2009-11-05 |
| CA2722658C (en) | 2018-09-18 |
| MX2010011846A (es) | 2011-04-11 |
| EP2282719A4 (en) | 2011-11-09 |
| JP5539965B2 (ja) | 2014-07-02 |
| CN102076326B (zh) | 2015-12-02 |
| CA2722658A1 (en) | 2009-11-05 |
| BRPI0911612A2 (pt) | 2015-12-15 |
| EP2282719B1 (en) | 2018-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX337862B (es) | Composiciones y métodos para el tratamiento de la esclerosis multiple. | |
| MX2010004554A (es) | Composiciones y métodos para el tratamiento de inflamación. | |
| MX2013001636A (es) | Composiciones y metodos para el tratamiento de taupatias | |
| MX2011011333A (es) | Composiciones y metodos para tratar la resistencia a la insulina y la diabetes mellituscampo de la invencion. | |
| WO2009134929A3 (en) | Compositions and methods for treating digestive disorders | |
| EA201170601A1 (ru) | Модуляторы регулятора трансмембранной проводимости при муковисцидозе | |
| ES2525238T3 (es) | Método para preparar emulsiones aceite-en-agua a partir de concentrados de geles autoemulsionantes | |
| EP4272731A3 (en) | Compositions for the delivery of therapeutic agents and methods of use and making thereof | |
| CL2007000813A1 (es) | Metodos para preparar agregados de micelas de proteina de suero y un agente activo; agregados; producto alimenticio o producto cosmetico; y uso de las micelas de proteina de suero. | |
| TR201908163T4 (tr) | Tnf aktivitesinin modülatörleri olarak pirazolopiridin türevleri. | |
| EA201270815A1 (ru) | Модуляторы рецепторов эстрогена и их применение | |
| GT200600112A (es) | Composiciiones de tigeciclina y metodos de preparacion | |
| MX2011011942A (es) | Metodos para el diagnostico de trastornos oncologicos usando intercambiadores epimetabolicos, moleculas intracelulares multidimensionales, o influyentes ambientales. | |
| TW200712059A (en) | Ionic liquids of low viscosity | |
| EA201190295A1 (ru) | Композиции для дермальной доставки, содержащие комплексы активного агента с частицами фосфата кальция, и способы их применения | |
| BRPI0810874A2 (pt) | Líquido iônico, proceso para preparar um líquido iônico, e, uso de líquidos iônicos. | |
| MX2010008610A (es) | Emulsiones de aceite en agua estabilizadas que incluyen ingredientes activos agricolamente. | |
| DE502005006577D1 (de) | 2-phenylethylbenzoat in kosmetischen öl-in-wasser-uv-lichtschutzemulsionen | |
| TR200806298A2 (tr) | Farmasötik formülasyon | |
| DE602006012532D1 (de) | Zellfreie in-vitro-transkription und translation von membranproteinen in gebundene planare lipidschichten | |
| EP4293116A3 (fr) | Fibrinogène liquide stable | |
| ATE531703T1 (de) | Benzochromenderivate | |
| BR112014004263A2 (pt) | composições fixadoras de cabelo | |
| NO20065806L (no) | Peptid-baserte forbindelser | |
| WO2005069855A3 (en) | Modulators of angiogenesis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |